MyChesCo on MSN10d
Ocugen Advances OCU200 Clinical Trial Amid Promising Safety ResultsMALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic ...
Paulick Report on MSN10mon
Study: Iron Inflammatory Markers May Indicate Severity Of ColicCanola and a team of researchers analyzed ferritin, which stores iron and increases during acute inflammation, and ...
After review by the Data and Safety Monitoring Board, the dosing of OCU200 in patients with diabetic macular edema (DME) will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback